Aptus Capital Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Aptus Capital Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.2K	Buy	27,966 +735	+3%	+$1.56K	﹤0.01%	1346
2026 Q1	$59.1K	Buy	27,231 +621	+2%	+$1.54K	﹤0.01%	1254
2025 Q4	$47.9K	Buy	26,610 +883	+3%	+$1.8K	﹤0.01%	1297
2025 Q3	$57.1K	Buy	25,727 +874	+4%	+$1.42K	﹤0.01%	1213
2025 Q2	$36.8K	Buy	24,853 +915	+4%	+$1.87K	﹤0.01%	1214
2025 Q1	$61.3K	Buy	23,938 +575	+2%	+$1.37K	﹤0.01%	1082
2024 Q4	$43.9K	Buy	23,363 +1,026	+5%	+$1.45K	﹤0.01%	1124
2024 Q3	$22.8K	Buy	22,337 +1,412	+7%	+$1.49K	﹤0.01%	1020
2024 Q2	$24.5K	Buy	20,925 +1,304	+7%	+$1.54K	﹤0.01%	960
2024 Q1	$24.7K	Buy	19,621 +1,099	+6%	+$1.64K	﹤0.01%	949
2023 Q4	$33K	Buy	18,522 +1,025	+6%	+$1.59K	﹤0.01%	715
2023 Q3	$29K	Buy	17,497 +737	+4%	+$1.32K	﹤0.01%	728
2023 Q2	$33.5K	Buy	16,760 +750	+5%	+$1.79K	﹤0.01%	614
2023 Q1	$33.6K	Buy	+16,010	New	+$28.1K	﹤0.01%	595
2022 Q4	–	Sell	-13,957	Closed	-$15K	–	834
2022 Q3	$15K	Buy	13,957 +1,539	+12%	+$1.7K	﹤0.01%	635
2022 Q2	$14K	Buy	12,418 +967	+8%	+$1.13K	﹤0.01%	556
2022 Q1	$12K	Buy	+11,451	New	+$10.5K	﹤0.01%	595
2019 Q4	–	Sell	-3,638	Closed	-$7K	–	557
2019 Q3	$7K	Hold	3,638	–	–	﹤0.01%	446
2019 Q2	$17K	Buy	+3,638	New	+$15.4K	﹤0.01%	329

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Aptus Capital Advisors's PLX Position: Q2 2026 in Review

Aptus Capital Advisors increased its Protalix BioTherapeutics (PLX) stake by 2.7% in Q2 2026, buying an estimated $1.56K and bringing the position to 27,966 shares worth $65.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1346.

Aptus Capital Advisors first reported a position in PLX in Q2 2019 and has held it in 19 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Aptus Capital Advisors held 27,966 shares of Protalix BioTherapeutics worth $65.2K as of Q2 2026.
Aptus Capital Advisors bought 735 Protalix BioTherapeutics shares in Q2 2026, an estimated $1.56K.
Protalix BioTherapeutics made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #1346 holding.
Aptus Capital Advisors first reported a position in Protalix BioTherapeutics in Q2 2019 and has held it in 19 quarters since.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.